In comparison to static pre- and post-NACT Ki-67, the relative change captures the tumour response to NACT and seems to be especially valuable in HER2+ subtype where absolute post-NACT Ki-67 values may be more heterogeneous due to targeted anti-HER2 therapy. The gene discussed is ERBB2; the disease is neoplasm.